REFERENCES
- Storb R F, Lucarelli G, McSweeney P A, Childs R W. Hematopoietic cell transplantation for benign hematological disorders and solid tumors. Hematology (Am Soc Hematol Educ Program) 2003; 372–397
- La Nasa G, Argiolu F, Giardini C, et al. Unrelated bone marrow transplantation for beta-thalassemia patients: the experience of the Italian Bone Marrow Transplant Group. Ann N Y Acad Sci 2005; 1054: 186–195, [INFOTRIEVE], [CROSSREF]
- Borgna-Pignatti C, Rugolotto S, De Stefano P, Zhao H, Cappellini M D, Del Vecchio G C, et al. Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine. Haematologica 2004; 89: 1187–1193, [INFOTRIEVE]
- Borgna-Pignatti C, Cappellini M D, De Stefano P, Del Vecchio G C, Forni G L, Gamberini M R, et al. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Blood 2006; 107: 3733–3737, [INFOTRIEVE], [CROSSREF]
- Hoyes K P, Porter J B. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools. Br J Haematol 1993; 85: 393–400, [INFOTRIEVE]
- Cappellini M D, Cohen A, Piga A, et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455–3462, [INFOTRIEVE], [CROSSREF]
- Pennell D J, Berdoukas V, Karagiorga M, et al. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Blood 2006; 107: 3738–3744, [INFOTRIEVE], [CROSSREF]
- Westwood M A, Firmin D N, Gildo M, et al. Intercentre reproducibility of magnetic resonance T2* measurements of myocardial iron in thalassaemia. Int J Cardiovasc Imaging 2005; 21: 531–538, [INFOTRIEVE], [CROSSREF]
- Cappellini M D, Grespi E, Cassinerio E, Bignamini D, Fiorelli G. Coagulation and splenectomy: an overview. Ann N Y Acad Sci 2005; 1054: 317–324, [INFOTRIEVE], [CROSSREF]
- Rahav G, Volach V, Shapiro M, Rund D, Rachmilewitz E A, Goldfarb A. Severe infections in thalassaemic patients: prevalence and predisposing factors. Br J Haematol 2006; 133: 667–674, [INFOTRIEVE], [CROSSREF]
- McCormick M K, Dockter J, Linnen J M, Kolk D, Wu Y, Giachetti C. Evaluation of a new molecular assay for detection of human immunodeficiency virus type 1 RNA, hepatitis C virus RNA, and hepatitis B virus DNA. J Clin Virol 2006; 36: 166–176, [INFOTRIEVE], [CROSSREF]
- Inati A, Taher A, Ghorra S, et al. Efficacy and tolerability of peginterferon alpha-2a with or without ribavirin in thalassaemia major patients with chronic hepatitis C virus infection. Br J Haematol 2005; 130: 644–646, [INFOTRIEVE], [CROSSREF]
- Borgna-Pignatti C, Vergine G, Lombardo T, et al. Hepatocellular carcinoma in the thalassaemia syndromes. Br J Haematol 2004; 124: 114–117, [INFOTRIEVE], [CROSSREF]
- Singer S T, Kuypers F A, Styles L, Vichinsky E P, Foote D, Rosenfeld H. Pulmonary hypertension in thalassemia: Association with platelet activation and hypercoagulable state. Am J Hematol Jun 22, 2006, [Epub ahead of print]
- Aessopos A, Farmakis D, Loukopoulos D. Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. Blood 2002; 99: 30–35, [INFOTRIEVE], [CROSSREF]
- Mantovani L G, Ravera S, Cappellini M D, the ITHACA Study Group. Cost assessment of beta thalassemia major: the ITHACA study. XI Congress of the European Hematology Association, Amsterdam, 2006, Abstract 0572